Literature DB >> 32014917

Rosmarinic Acid/ Blue Light Combination Treatment Inhibits Head and Neck Squamous Cell Carcinoma In Vitro.

Christi N Waer1, Preet Kaur1, Zohra Tumur1, Dee Dee Hui1, Bonnie LE1, Carlos Guerra1, Bradley Henson1, Dalia Seleem1, Jill Lewis2.   

Abstract

BACKGROUND/AIM: This study investigated a novel combined therapy of rosmarinic acid (RA)/blue light on head and neck squamous cell carcinoma (HNSCC) cell proliferation in vitro.
MATERIALS AND METHODS: HNSCC cells were exposed to BL (500 mW/cm2) for 90 s, and incubated with 80 μg/ml RA for 1 hour. Cell viability was determined after 24 h using WST-1 assay. Western blot was used to detect treatment-induced changes in epidermal growth factor receptor (EGFR) activation. Hydrogen peroxide (H2O2) and nitric oxide levels were quantified using CM-H2DCFH-DA assays. Apoptosis was assessed using Annexin V/PI staining and flow cytometry.
RESULTS: RA/blue light treatment resulted in a significant reduction in cell viability, EGFR activation and H2O2 levels in all HNSCC cell lines. However, no significant changes in NO production or apoptosis induction were found.
CONCLUSION: RA/blue light effectively decreased HNSCC cell proliferation through reduction in EGFR activation and H2O2 production, and not via induction of apoptosis. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  EGF receptor; Head and neck cancer; light; oxidative stress; phytochemicals

Mesh:

Substances:

Year:  2020        PMID: 32014917     DOI: 10.21873/anticanres.14006

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Continuous flow synthesis of lipophilic cations derived from benzoic acid as new cytotoxic chemical entities in human head and neck carcinoma cell lines.

Authors:  Mabel Catalán; Vicente Castro-Castillo; Javier Gajardo-de la Fuente; Jocelyn Aguilera; Jorge Ferreira; Ricardo Ramires-Fernandez; Ivonne Olmedo; Alfredo Molina-Berríos; Charlotte Palominos; Marcelo Valencia; Marta Domínguez; José A Souto; José A Jara
Journal:  RSC Med Chem       Date:  2020-08-19

Review 2.  Novel possibility for cutaneous melanoma treatment by means of rosmarinic acid action on purinergic signaling.

Authors:  Gilnei Bruno da Silva; Milena Ayumi Yamauchi; Daniela Zanini; Margarete Dulce Bagatini
Journal:  Purinergic Signal       Date:  2021-11-05       Impact factor: 3.765

Review 3.  Biomedical features and therapeutic potential of rosmarinic acid.

Authors:  Saba Noor; Taj Mohammad; Malik Abdul Rub; Ali Raza; Naved Azum; Dharmendra Kumar Yadav; Md Imtaiyaz Hassan; Abdullah M Asiri
Journal:  Arch Pharm Res       Date:  2022-04-07       Impact factor: 6.010

4.  Rosmarinic acid inhibits proliferation and migration, promotes apoptosis and enhances cisplatin sensitivity of melanoma cells through inhibiting ADAM17/EGFR/AKT/GSK3β axis.

Authors:  Lin Huang; Jiangyan Chen; Jin Quan; Debing Xiang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.